GSK terminates LAG-3 single anti-ulcerative enteritis Phase II study

On January 22, Immutep announced that its partner GSK had terminated THE LAG-3 single anti-GSK2831781 (IMP731) Phase II clinical research project for active ulcerative enteritis.
GSK made this decision after completing a scheduled in-period analysis and discussion with the Data Assessment Committee, and further evaluation of efficacy, safety and biological mechanisms is still under way to determine the next clinical development plan for GSK2831781.
LAG-3 (lymphocyte activation gene 3, LAG-3, CD223) is an immune checkpoint-like protein that is mainly expressed in active T-cells, NK cells, B-cells, and plasma cell dendrine cells.
LAG-3 can be combined with MHC II molecules to reduce the activity of T cells.
, LAG-3 also enhances the inhibitory activity of regulatory T-cells (Tregs).
the use of therapeutic antibodies to inhibit LAG-3, can lift the inhibition of T cells, enhance the body's immune response.
in many autoimmune diseases, chronic T-cell activation is one of the main causes of disease.
GSK2831781 is a cytotoxic antibody that depletes activated T cells and could theoretically be used to treat chronic autoimmune diseases.
6 January 2011, GSK and Immutep reached an agreement to receive a global exclusive development interest of 64 million pounds ($100 million, including down payments and mileage) from GSK2831781.
GSK will be subject to additional sales royalties if future products are available.
GSK's partnership with Immutep remains valid despite the termination of phase II of the project for ulcerative enteritis, GSK retains a global exclusive interest in GSK2831781.
addition to ulcerative enteritis, GSK is also developing GSK2831781 psoriasis adaptation, which is currently in Phase I.
Immutep is a pioneer in the development of LAG-3 immunotherapy for cancer and autoimmune diseases, and in addition to GSK's GSK2831781, there are three other core LAG-3 products under development, including first in class antigen delivery cells (A PC) activator Eftilagimod Alpha (LAG-3 fusion protein, in collaboration with Pfizer, Merca East, Eton, Eton), tumor-directed ieramilimab (which has granted global rights to Novarma), and LAG-3 agonist IMP761 intended for use in autoimmune diseases.
GSK's termination of GSK2831781's ulcerative enteritis Phase II project will not affect Immutep's plans for the development of three other products.